Compare SNDX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNDX | TSLX |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2014 | 2011 |
| Metric | SNDX | TSLX |
|---|---|---|
| Price | $24.21 | $18.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $84.17 | $21.72 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 11.55% |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ 1.81 |
| Revenue | ★ $172,352,000.00 | N/A |
| Revenue This Year | $112.05 | N/A |
| Revenue Next Year | $51.24 | $1.92 |
| P/E Ratio | ★ N/A | $9.84 |
| Revenue Growth | ★ 627.84 | N/A |
| 52 Week Low | $8.59 | $16.99 |
| 52 Week High | $25.44 | $25.17 |
| Indicator | SNDX | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 65.43 | 45.33 |
| Support Level | $19.46 | $17.15 |
| Resistance Level | $25.16 | $22.46 |
| Average True Range (ATR) | 1.09 | 0.55 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 72.18 | 66.67 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.